Christopher Raymond
Stock Analyst at Piper Sandler
(2.67)
# 1,935
Out of 5,150 analysts
140
Total ratings
52.17%
Success rate
1.73%
Average return
Main Sectors:
Stocks Rated by Christopher Raymond
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| COGT Cogent Biosciences | Maintains: Overweight | $39 → $52 | $37.02 | +40.46% | 2 | Feb 18, 2026 | |
| ARDX Ardelyx | Upgrades: Overweight | $10 → $16 | $6.65 | +140.60% | 11 | Jan 9, 2026 | |
| LXEO Lexeo Therapeutics | Initiates: Strong Buy | $25 | $7.24 | +245.30% | 1 | Dec 18, 2025 | |
| TSHA Taysha Gene Therapies | Initiates: Strong Buy | $13 | $4.64 | +180.17% | 3 | Oct 21, 2025 | |
| MGTX MeiraGTx Holdings | Initiates: Strong Buy | $29 | $7.41 | +291.36% | 2 | Oct 21, 2025 | |
| ABVX ABIVAX Société Anonyme | Maintains: Overweight | $42 → $70 | $116.77 | -40.05% | 2 | Jul 23, 2025 | |
| BIIB Biogen | Maintains: Neutral | $135 → $115 | $189.94 | -39.45% | 21 | Apr 29, 2025 | |
| ALXO ALX Oncology Holdings | Maintains: Overweight | $8 → $9 | $2.19 | +310.96% | 6 | Mar 6, 2025 | |
| BMRN BioMarin Pharmaceutical | Maintains: Overweight | $122 → $126 | $60.43 | +108.51% | 15 | Feb 20, 2025 | |
| QTTB Q32 Bio | Downgrades: Neutral | $20 → $4 | $4.73 | -15.43% | 3 | Feb 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $220 → $227 | $236.19 | -3.89% | 12 | Jan 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $535 → $533 | $477.89 | +11.53% | 8 | Jan 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $1,195 → $1,013 | $787.50 | +28.63% | 7 | Jan 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $135 → $140 | $21.80 | +542.20% | 5 | Jan 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $72 | $55.49 | +29.75% | 1 | Jan 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $3 → $13 | $3.10 | +319.35% | 2 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $60 → $75 | $9.15 | +719.67% | 4 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $66 → $76 | $10.61 | +616.31% | 7 | Sep 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $10 | $0.33 | +2,913.86% | 2 | Sep 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $33 | $35.27 | -6.44% | 1 | Aug 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $2 → $4 | $1.25 | +220.00% | 3 | May 31, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $293 → $288 | $379.27 | -24.06% | 16 | Apr 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $41 | $28.19 | +45.44% | 1 | Feb 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $28 | $43.23 | -35.23% | 1 | Jul 26, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $40 | $102.67 | -61.04% | 1 | Aug 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $90 | $6.14 | +1,365.80% | 1 | Jul 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $96 | $1.73 | +5,449.13% | 2 | Mar 13, 2020 |
Cogent Biosciences
Feb 18, 2026
Maintains: Overweight
Price Target: $39 → $52
Current: $37.02
Upside: +40.46%
Ardelyx
Jan 9, 2026
Upgrades: Overweight
Price Target: $10 → $16
Current: $6.65
Upside: +140.60%
Lexeo Therapeutics
Dec 18, 2025
Initiates: Strong Buy
Price Target: $25
Current: $7.24
Upside: +245.30%
Taysha Gene Therapies
Oct 21, 2025
Initiates: Strong Buy
Price Target: $13
Current: $4.64
Upside: +180.17%
MeiraGTx Holdings
Oct 21, 2025
Initiates: Strong Buy
Price Target: $29
Current: $7.41
Upside: +291.36%
ABIVAX Société Anonyme
Jul 23, 2025
Maintains: Overweight
Price Target: $42 → $70
Current: $116.77
Upside: -40.05%
Biogen
Apr 29, 2025
Maintains: Neutral
Price Target: $135 → $115
Current: $189.94
Upside: -39.45%
ALX Oncology Holdings
Mar 6, 2025
Maintains: Overweight
Price Target: $8 → $9
Current: $2.19
Upside: +310.96%
BioMarin Pharmaceutical
Feb 20, 2025
Maintains: Overweight
Price Target: $122 → $126
Current: $60.43
Upside: +108.51%
Q32 Bio
Feb 11, 2025
Downgrades: Neutral
Price Target: $20 → $4
Current: $4.73
Upside: -15.43%
Jan 27, 2025
Maintains: Overweight
Price Target: $220 → $227
Current: $236.19
Upside: -3.89%
Jan 27, 2025
Maintains: Overweight
Price Target: $535 → $533
Current: $477.89
Upside: +11.53%
Jan 27, 2025
Maintains: Overweight
Price Target: $1,195 → $1,013
Current: $787.50
Upside: +28.63%
Jan 13, 2025
Maintains: Overweight
Price Target: $135 → $140
Current: $21.80
Upside: +542.20%
Jan 10, 2025
Initiates: Overweight
Price Target: $72
Current: $55.49
Upside: +29.75%
Nov 18, 2024
Upgrades: Overweight
Price Target: $3 → $13
Current: $3.10
Upside: +319.35%
Nov 6, 2024
Maintains: Overweight
Price Target: $60 → $75
Current: $9.15
Upside: +719.67%
Sep 23, 2024
Maintains: Overweight
Price Target: $66 → $76
Current: $10.61
Upside: +616.31%
Sep 3, 2024
Maintains: Overweight
Price Target: $10
Current: $0.33
Upside: +2,913.86%
Aug 15, 2024
Initiates: Overweight
Price Target: $33
Current: $35.27
Upside: -6.44%
May 31, 2023
Upgrades: Overweight
Price Target: $2 → $4
Current: $1.25
Upside: +220.00%
Apr 28, 2023
Maintains: Overweight
Price Target: $293 → $288
Current: $379.27
Upside: -24.06%
Feb 3, 2023
Initiates: Overweight
Price Target: $41
Current: $28.19
Upside: +45.44%
Jul 26, 2022
Initiates: Overweight
Price Target: $28
Current: $43.23
Upside: -35.23%
Aug 23, 2021
Initiates: Overweight
Price Target: $40
Current: $102.67
Upside: -61.04%
Jul 12, 2021
Initiates: Neutral
Price Target: $90
Current: $6.14
Upside: +1,365.80%
Mar 13, 2020
Downgrades: Neutral
Price Target: $96
Current: $1.73
Upside: +5,449.13%